| Pack Size | Single Vial, 10-Pack |
|---|
Selank is a synthetic seven-residue heptapeptide. Selank is a synthetic seven-residue heptapeptide with sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The compound is a tuftsin analogue — tuftsin is the four-residue Thr-Lys-Pro-Arg sequence found in the immunoglobulin G heavy-chain Fc region, with native immunomodulatory activity. Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide for proteolytic stability. The compound has been studied across multiple research streams covering its mechanism, biological-activity profile, and translational-research framings. Every Ronin batch is independently verified by Janoshik Analytical using HPLC for purity and mass spectrometry for identity, with the minimum acceptance threshold set at 99 percent purity by HPLC. Supplied as a lyophilized powder in a sealed glass vial, 10 mg per vial. For laboratory research use only — not for human or veterinary use.
Description
Selank is a synthetic seven-residue heptapeptide with sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The compound is a tuftsin analogue — tuftsin is the four-residue Thr-Lys-Pro-Arg sequence found in the immunoglobulin G heavy-chain Fc region, with native immunomodulatory activity. Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide for proteolytic stability.
Selank has been investigated for anxiolytic activity through GABAergic neurotransmission modulation, BDNF (brain-derived neurotrophic factor) regulation in the hippocampus and prefrontal cortex, and broader immunomodulatory framings derived from its tuftsin-analogue origins. The compound was developed in Russia as part of a peptide-bioregulator research programme.
The compound is supplied as a lyophilized white-to-off-white powder in a sealed amber-glass vial under inert gas. Each vial contains 10 mg of compound. Reconstitution with bacteriostatic water is required before the compound can be drawn into an insulin syringe. Researchers planning bench preparations should review the Reconstitution accordion below for mechanics.
Selank has been characterised across an expanding research literature spanning Anxiolytic and stress-response research, BDNF and memory-impairment models, GABAergic neurotransmission gene expression, cytokine modulation under stress conditions.
The 2019 Kolik paper in Bulletin of Experimental Biology and Medicine characterised Selank protection against ethanol-induced memory impairment through BDNF regulation in hippocampus and prefrontal cortex (PMID 31625062). The 2016 Volkova paper in Frontiers in Pharmacology documented Selank effects on GABAergic neurotransmission gene expression (PMID 26924987). The 2017 Filatova paper extended findings to IMR-32 cell-line systems comparing Selank, GABA, and olanzapine (PMID 28293190). The 2021 Leonidovna paper characterised cytokine modulation under social-stress conditions (PMID 32621722).
Across the literature the compound appears under several alternate identifiers: Selank; TKPRPGP heptapeptide; tuftsin analogue with PGP extension. The CAS registry number 129954-34-3 anchors the canonical chemical identifier.
No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared Selank for therapeutic use in humans or animals. The compound has not progressed through a drug-approval pathway in any major jurisdiction. Ronin Peptides ships the compound exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.
Mechanism in research literature
Selank has been investigated for anxiolytic activity through GABAergic neurotransmission modulation, BDNF (brain-derived neurotrophic factor) regulation in the hippocampus and prefrontal cortex, and broader immunomodulatory framings derived from its tuftsin-analogue origins. The compound was developed in Russia as part of a peptide-bioregulator research programme.
The 2019 Kolik paper in Bulletin of Experimental Biology and Medicine characterised Selank protection against ethanol-induced memory impairment through BDNF regulation in hippocampus and prefrontal cortex (PMID 31625062). The 2016 Volkova paper in Frontiers in Pharmacology documented Selank effects on GABAergic neurotransmission gene expression (PMID 26924987). The 2017 Filatova paper extended findings to IMR-32 cell-line systems comparing Selank, GABA, and olanzapine (PMID 28293190). The 2021 Leonidovna paper characterised cytokine modulation under social-stress conditions (PMID 32621722).
Multiple groups have studied, examined, and characterised the compound across in vitro, ex vivo, and animal-model preparations. The mechanism research has produced both basic-science findings on the molecular targets and translational-research observations in disease-model systems. The 2026 broader peptide-therapy reviews (PMID 41966639) place this compound class in the wider research-context of unapproved compounds under active investigation.
Researchers planning new work should consult the most current literature on this compound class to position findings against the broader mechanism-niche framework. Independent groups have observed consistent patterns across the published research record, providing cross-laboratory replication for the core mechanism findings documented in the foundational papers cited above.
Recent broader peptide-therapy reviews compile contemporary research framings around the broader compound class within which this molecule sits. The 2026 Sports Medicine and JAAOS Global Research and Reviews papers (PMID 41966639, PMID 41490200) place multiple compounds — including this one — into the wider research context of unapproved compounds under active investigation, with attention to both the mechanism findings and the regulatory framing that researchers consulting these reviews should weigh equally.
Studied properties
The published research record on Selank spans multiple decades. Most of this corpus consists of cell-culture and rodent-model investigations. The foundational mechanism work has been complemented by translational-research investigations in disease-model systems and by recent contemporary reviews compiling the broader research framework.
The 2019 Kolik paper in Bulletin of Experimental Biology and Medicine characterised Selank protection against ethanol-induced memory impairment through BDNF regulation in hippocampus and prefrontal cortex (PMID 31625062). The 2016 Volkova paper in Frontiers in Pharmacology documented Selank effects on GABAergic neurotransmission gene expression (PMID 26924987). The 2017 Filatova paper extended findings to IMR-32 cell-line systems comparing Selank, GABA, and olanzapine (PMID 28293190). The 2021 Leonidovna paper characterised cytokine modulation under social-stress conditions (PMID 32621722).
Independent replication of the foundational findings across multiple research groups provides cross-laboratory credibility for the core mechanism observations. The pattern of consistent findings across in vitro, ex vivo, and animal-model contexts has shaped the contemporary research-context framing for the compound.
Translation to human clinical application has been narrower than the breadth of the preclinical literature would suggest. The contemporary research framing places the compound in a research-supply position rather than a clinical-development position. Researchers consulting recent reviews (PMID 41966639) should attend to the regulatory framing as much as the mechanism framing.
Recent literature has expanded the application bracket through novel research streams. Investigators have studied the compound in combination with other research molecules, in biomaterial-integrated delivery formats, and in cell-type-specific contexts that broaden the mechanism understanding documented in foundational papers. The expansion-era literature continues to add depth to the compound's research profile.
Cross-stream research framings have continued to expand the application bracket through novel investigation contexts. Investigators have studied the compound across cell-type-specific exposures, biomaterial-integrated delivery formats, and combination protocols with adjacent research compounds. The cumulative literature represents an active expansion-era research stream where new findings appear regularly across the international peer-reviewed publication record. Researchers consulting recent reviews should attend to both the foundational mechanism papers cited in the references and the contemporary expansion-era publications that document ongoing methodological refinements and emerging research applications.
The published research record is broadly accessible through major scientific databases including PubMed, Web of Science, and Scopus, with PMID identifiers cited inline throughout this page providing direct access to the foundational literature. Researchers planning new experimental work should consult the most recent literature beyond the citations provided here, since the research record continues to expand and the contemporary research-context framing benefits from inclusion of the most current findings. Independent groups have characterised the compound across overlapping research model systems, providing cross-laboratory replication for the core observations documented in the foundational papers.
Compound specifications
| Specification | Value |
|---|---|
| Common name | Selank |
| Alternate names | Selank; TKPRPGP heptapeptide; tuftsin analogue with PGP extension |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) |
| Molecular formula | C33H57N11O9 |
| Molecular weight | 751.88 g/mol |
| CAS number | 129954-34-3 |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
Storage and handling
Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.
Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands.
After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window for a reconstituted preparation is four to six weeks at fridge temperature. The 0.9% benzyl alcohol in bacteriostatic water suppresses microbial growth but does not arrest hydrolysis, oxidation, or aggregation processes accumulating in any aqueous compound solution over time.
When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on molecular structure, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature.
The reconstituted product should be visually clear and colourless. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Primary research area | Documented mechanism (preclinical) | Format at Ronin |
|---|---|---|---|
| Selank | Anxiolytic; BDNF; GABAergic | Tuftsin analogue heptapeptide | 10 mg vial |
| Semax | Cognitive; neurotrophic; ACTH(4-10) analog | BDNF/trkB modulation | 10 mg vial |
| Epitalon | Aging research; pineal axis | Telomerase activation | 10 mg vial |
Selank sits within Ronin's cognitive compound category, alongside related compounds in the catalog. Researchers exploring related research areas often examine Selank in combination with other compounds in the same mechanism niche, or comparatively against compounds that engage adjacent pathways.
Reconstitution and laboratory handling
A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. With 1 mL: 10 mg/mL. With 5 mL: 2 mg/mL.
Reconstitution procedure:
- Bring both vials — compound and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures compound at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.
For dose-volume calculations on insulin syringes, use the Ronin reconstitution calculator.
In published preclinical research, Selank has been administered across multiple model systems with varying routes documented in the literature (PMID 36322304, PMID 32621722, PMID 31243679, PMID 31625062). These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.
Frequently asked questions
What is Selank?
Selank is a synthetic seven-residue heptapeptide. Selank is a synthetic seven-residue heptapeptide with sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The compound is a tuftsin analogue — tuftsin is the four-residue Thr-Lys-Pro-Arg sequence found in the immunoglobulin G heavy-chain Fc region, with native immunomodulatory activity. Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide for proteolytic stability. The compound has been characterised across multiple research streams covering Anxiolytic and stress-response research, BDNF and memory-impairment models, GABAergic neurotransmission gene expression, cytokine modulation under stress conditions. Ronin supplies the compound as a lyophilized vial reconstituted with bacteriostatic water at the bench. Sale is limited to laboratory research applications; human and veterinary use are excluded.
What is the regulatory status?
No regulatory body — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has approved Selank as a drug for human or veterinary use. The compound has not progressed through a drug-approval pathway in any major jurisdiction.
The compound is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is Selank verified?
Each batch passes through Janoshik Analytical — an independent peptide-analytics lab — for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com. To pull the COA covering the batch on your order, email support@roninpeptides.ca from the address used at checkout, with your order number; the typical reply turnaround is well under 24 hours.
How is Selank reconstituted?
A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. With 1 mL: 10 mg/mL. With 5 mL: 2 mg/mL. Inject the water against the inside wall of the vial — never directly onto the lyophilized powder, which causes foaming and surface denaturation. Swirl gently or invert slowly until fully dissolved (typically 30–60 seconds). Refrigerate at 2–8 °C immediately. Use the Ronin reconstitution calculator for non-standard volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch. COAs are not published publicly to protect supply-chain privacy and prevent competitor scraping.
References
- Konstantinopolsky MA et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal. Bull Exp Biol Med. 2022. PMID: 36322304 | doi:10.1007/s10517-022-05624-x
- Leonidovna YA et al. The Influence of Selank on the Level of Cytokines Under Social Stress. Curr Rev Clin Exp Pharmacol. 2021. PMID: 32621722 | doi:10.2174/1574884715666200704152810
- Fomenko EV et al. Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bull Exp Biol Med. 2019. PMID: 31243679 | doi:10.1007/s10517-019-04512-1
- Kolik LG et al. Selank Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content. Bull Exp Biol Med. 2019. PMID: 31625062 | doi:10.1007/s10517-019-04588-9
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016. PMID: 26924987 | doi:10.3389/fphar.2016.00031
- Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2017. PMID: 28293190 | doi:10.3389/fphar.2017.00089
- Khavinson VKh et al. Peptides and Ageing. Neuro Endocrinol Lett. 2002. PMID: 12374906
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Med. 2026. PMID: 41966639 | doi:10.1007/s40279-026-02437-0
